Aldeyra Therapeutics Inc logo

ALDX

Aldeyra Therapeutics Inc

$6.94

Earnings Summary

Revenue
$0Mn
Net Profits
$-16.79Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Aldeyra Therapeutics Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Aldeyra Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Aldeyra Therapeutics Inc’s net profit fell -48.7% since last year same period to $-16.79Mn in the Q1 2022. On a quarterly growth basis, Aldeyra Therapeutics Inc has generated 99.97% jump in its net profits since last 3-months.

Net Profit Margins:

Aldeyra Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Aldeyra Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Aldeyra Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.31
EPS Estimate Current Year
-0.31

Highlights

EPS Estimate Current Quarter:

Aldeyra Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.31 - a 0% jump from last quarter’s estimates.

EPS Estimate Current Year:

Aldeyra Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.31.

Key Ratios

Key ratios of the Aldeyra Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.29
Return on Assets (ROA)
-0.18
Return on Equity (ROE)
-0.32
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Aldeyra Therapeutics Inc’s earning per share (EPS) fell -16% since last year same period to -0.29 in the Q1 2022. This indicates that the Aldeyra Therapeutics Inc has generated -16% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Aldeyra Therapeutics Inc’s return on assets (ROA) stands at -0.18.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Aldeyra Therapeutics Inc’s return on equity (ROE) stands at -0.32.

Dividend Per Share (DPS):

Aldeyra Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.31
-0.29
6.45%

Company Information

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.

Organisation
Aldeyra Therapeutics Inc
Employees
11
Industry
Health Technology